- Home
- BIIB vs NTR Comparison
BIIB vs NTR Comparison
Compare BIIB & NTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- NTR
- Stock Information
- Founded
- BIIB 1978
- NTR 2017
- Country
- BIIB United States
- NTR Canada
- Employees
- BIIB N/A
- NTR N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- NTR Agricultural Chemicals
- Sector
- BIIB Health Care
- NTR Industrials
- Exchange
- BIIB Nasdaq
- NTR Nasdaq
- Market Cap
- BIIB 18.8B
- NTR 25.5B
- IPO Year
- BIIB 1991
- NTR N/A
- Fundamental
- Price
- BIIB $125.00
- NTR $58.22
- Analyst Decision
- BIIB Buy
- NTR Hold
- Analyst Count
- BIIB 27
- NTR 16
- Target Price
- BIIB $188.17
- NTR $60.63
- AVG Volume (30 Days)
- BIIB 1.3M
- NTR 2.2M
- Earning Date
- BIIB 07-31-2025
- NTR 08-06-2025
- Dividend Yield
- BIIB N/A
- NTR 3.72%
- EPS Growth
- BIIB 26.39
- NTR N/A
- EPS
- BIIB 10.12
- NTR 1.06
- Revenue
- BIIB $9,816,400,000.00
- NTR $24,739,000,000.00
- Revenue This Year
- BIIB N/A
- NTR $5.84
- Revenue Next Year
- BIIB N/A
- NTR $2.49
- P/E Ratio
- BIIB $12.41
- NTR $53.96
- Revenue Growth
- BIIB 1.59
- NTR N/A
- 52 Week Low
- BIIB $110.04
- NTR $43.70
- 52 Week High
- BIIB $238.00
- NTR $65.08
- Technical
- Relative Strength Index (RSI)
- BIIB 45.14
- NTR 43.24
- Support Level
- BIIB $123.21
- NTR $57.23
- Resistance Level
- BIIB $129.27
- NTR $65.08
- Average True Range (ATR)
- BIIB 3.00
- NTR 1.32
- MACD
- BIIB -0.77
- NTR -0.58
- Stochastic Oscillator
- BIIB 21.06
- NTR 12.61
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About NTR Nutrien Ltd.
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients - nitrogen, potash, and phosphate - although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.